Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2014

View Archived Issues

Safety issues noted in phase I study of cabazitaxel in gastric adenocarcinoma

The Vanderbilt University patents novel mGlu5 receptor modulators

Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial

Simtuzumab well tolerated in phase I and II trials

Nektar Therapeutics reviews product development status for 2014

Preliminary trial results provided for selinexor in colorectal cancer

Hybrigenics achieves first milestone under USP collaboration

Novel antibodies for cancer presented by Regeneron Pharmaceuticals

4SC Discovery discloses new casein kinase inhibitors

French and Danish researchers patent new K(Ca)3.1 channel blockers

Cystadane approved in Japan for homocystinuria

A team in Israel divulges new anti-fibrinolytic compositions for coagulation

Roche and Genentech synthesize new pim kinase inhibitors

Amarin to appeal FDA's rescindment of ANCHOR SPA agreement

Novartis synthesizes new agents for macular degeneration and other disorders

Phase I study begins for hemophilia candidate ALN-AT3SC

Pluristem's phase I/II trial of PLX-PAD cells in muscle injury meets primary endpoints

New radioligands tested for assessment of AD in living subjects

GSK launches phase I trial of GSK-2879552 in relapsed/refractory SCLC

First trials in phase III bitopertin program miss primary endpoints

Novartis opens phase II study of VAY-736 in multiple sclerosis

Eculizumab receives FDA orphan drug designation for delayed graft function in renal transplantation

French authorities grant temporary authorization for use of Raxone in LHON

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...